AIDS reviewsPub Date : 2024-01-01DOI: 10.24875/AIDSRev.M25000079
Jorge Esteban-Sampedro, Mario Martín-Portugués, Pedro Durán-Del Campo, Román Fernández-Güitián, Jaime E Ruiz-Becerra, Víctor Moreno-Torres
{"title":"Castleman's disease: one disease, multiple etiologies.","authors":"Jorge Esteban-Sampedro, Mario Martín-Portugués, Pedro Durán-Del Campo, Román Fernández-Güitián, Jaime E Ruiz-Becerra, Víctor Moreno-Torres","doi":"10.24875/AIDSRev.M25000079","DOIUrl":"https://doi.org/10.24875/AIDSRev.M25000079","url":null,"abstract":"<p><p>Castleman disease (CD) comprises a heterogeneous group of rare lymphoproliferative disorders characterized by similar morphological features in nodal biopsies. Since Benjamin Castleman's initial description in 1956, our understanding of CD has progressed substantially. The intricate mechanisms underlying the four recognized subtypes of multicentric CD (MCD) have been studied thoroughly during recent decades. Major disease contributors include the identification of certain viral infections, namely human herpes virus-8 (HHV-8) and HIV; and the discovery of molecular and genetic mechanisms driving disease development and progression and the consequent development of biological targeted therapies, notably siltuximab and rituximab. The CD has been associated with autoimmune, autoinflammatory, and hematological disorders. Along with epidemiological data, the current classification of CD encompasses unicentric CD and MCD. MCD is further subdivided into HHV-8-associated MCD, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin (POEMS)-associated MCD, and idiopathic MCD (iMCD), which includes thrombocytopenia, anasarca, fever, reticulin TAFRO-iMCD, and iMCD-not-otherwise-specified (iMCD-NOS). While these subtypes share common histological and similar clinical manifestations, they represent distinct conditions. In this review, we discuss the differences in epidemiology, pathophysiology, histology, clinical presentation, and treatment for all distinct CD subtypes. We focus on the role of viral infections in CD development and epidemiology. We finally end by acknowledging areas where further research is needed to uncover the complex nature of CD.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 4","pages":"158-172"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDS reviewsPub Date : 2024-01-01DOI: 10.24875/AIDSRev.24000008
Xinyu Huang, Junjie Ren, Liying Zhou, Xu Hui, Liping Guo, Li Xu, Kehu Yang
{"title":"Behavioral interventions for tobacco use in HIV-infected smokers: systematic review and pairwise, network meta-analysis of randomized trials.","authors":"Xinyu Huang, Junjie Ren, Liying Zhou, Xu Hui, Liping Guo, Li Xu, Kehu Yang","doi":"10.24875/AIDSRev.24000008","DOIUrl":"10.24875/AIDSRev.24000008","url":null,"abstract":"<p><p>Smoking among persons living with HIV infection (PLWH) is estimated to be 2-3 times greater than that in the general population. Data suggest that cigarette smoking is more common among PLWH because of several factors, including lower socioeconomic status, previous, or concurrent illicit drug and alcohol use, younger age, lower education level, and concomitant depressive symptoms. Cigarette smoking among PLWH has been associated with a higher risk of certain cancers and infections as well as lowered response to antiretroviral therapy. Randomized controlled trials on behavioral interventions for tobacco use among smokers with HIV were searched in the PubMed, Cochrane Library, EMBASE, and Web of Science databases. The retrieval period was from the inception of databases to November 2023. Network meta-analysis (NMA) was performed using the Stata 18.0 software with 19 studies (3190 subjects), of which 15 reported 7-day point prevalence abstinence and seven of which reported continuous abstinence. The NMA results showed that compared with general advice plus self-help brochure, text messaging (relative risk [RR] = 4.60, 95% confidence interval [CI], 1.12-18.81) and cell phone counseling (RR = 3.29, 95% CI, 1.71-6.32) were the most effective for 7-day point prevalence abstinence among smokers with HIV infection. Moreover, the meta-analysis showed that compared with smoking counseling and self-help brochures, continuous abstinence was statistically significantly enhanced after behavioral interventions (RR = 2.52, 95% CI, 1.51-4.20). The study revealed very low-to-high-quality evidence that text messaging, telephone counseling, and smoking cessation websites were effective for smokers with HIV infection.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 3","pages":"111-120"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDS reviewsPub Date : 2024-01-01DOI: 10.24875/AIDSRev.23000017
Mahmoud Kandeel
{"title":"Risk factors and mortality outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis.","authors":"Mahmoud Kandeel","doi":"10.24875/AIDSRev.23000017","DOIUrl":"10.24875/AIDSRev.23000017","url":null,"abstract":"<p><p>This study was performed to reveal the risk factors associated with mortality in people living with HIV (PLHIV) who were diagnosed with COVID-19. Studies reporting deaths among PLHIV and infected with SARS-CoV-2 were investigated. After protocol setup and registration, the extracted sources were categorized and assessed for quality. This study examined ten articles with a total of 46,136 patients. Patients aged ≥ 60 years (hazard ratio [HR] = 2.22; 95% CI: 1.617, 3.050; p < 0.001), male (HR = 1.668; 95% CI: 1.179, 2.361; p = 0.004), and people with diabetes (risk ratio [RR] = 3.34; 95% CI: 1.45, 7.68; p = 0.005) were at higher risk of death. Adherence to antiretroviral therapy (ART) reduced mortality risk (RR = 0.90; 95% CI: 0.83, 0.98; p = 0.02). Patients in the survival groups showed a statistically significant lower mean of C-reactive protein (mean difference = 114.08; 95% -74.05, 154.10; p < 0.001). Deceased patients showed higher mean levels of interleukin-6 (IL-6). Chronic respiratory disorders, hypertension, oxygen requirement, admission to an intensive care unit, D-dimer levels, and HIV viral load < 50 copies RNA/mL before admission did not show statistically significant differences between the deceased and survival groups. ART therapy reduced mortality risk (RR = 0.90; 95% 0.83, 0.98; p = 0.02). Identifying PLHIV at higher mortality risk could improve the outcomes of COVID-19 by stratifying these patients to the most effective treatment in a timely fashion.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 1","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140292519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDS reviewsPub Date : 2024-01-01DOI: 10.24875/AIDSRev.24000004
Pedro R S Almeida, Carlos A C Rafael, Victor Pimentel, Ana B Abecasis, Cruz S Sebastião, Joana de Morais
{"title":"Adherence to antiretroviral therapy among HIV-1 patients from sub-Saharan Africa: a systematic review.","authors":"Pedro R S Almeida, Carlos A C Rafael, Victor Pimentel, Ana B Abecasis, Cruz S Sebastião, Joana de Morais","doi":"10.24875/AIDSRev.24000004","DOIUrl":"https://doi.org/10.24875/AIDSRev.24000004","url":null,"abstract":"<p><p>More than two decades after introducing antiretroviral therapy (ART), several challenges still prevail in keeping well people living with HIV, even with \"Test and Treat\" and/or \"Rapid Start of ART\" initiatives, as well as the scale-up of ART worldwide to promote access and adherence to treatment. This review examined articles on ART adherence in Africa between 2016 and 2023, published in English and indexed in PubMed. A total of 16 articles out of 2415 were eligible and included for analyses. Overall, good ART adherence rates in sub-Saharan African (SSA) regions ranged from 43% to 84%. Rates in the center of the SSA region ranged from 58% to 80%, in the north from 50% to 83%, in the south from 77% to 84%, in the west from 43% to 60%, and in the east from 69% to 73%. Most African countries use self-reporting to assess treatment adherence, which is frequently unreliable. The main factors with negative influence on ART adherence were comorbidities, lack of motivation, socioeconomic difficulties, or side effects. Conclusion: Adherence to ART is a good indicator for controlling the spread of HIV in a given region. It is important to overcome the barriers that make it difficult to comply with ART and reinforce the factors that facilitate access to medication.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 3","pages":"102-110"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In silico drug repurposing approach to predict most effective HAART for HIV drug resistance variants prevalent in the Indian HIV-positive population.","authors":"Priya Kalsi, Priya Jain, Gitanjali Goyal, Himanshu Sharma","doi":"10.24875/AIDSRev.24000010","DOIUrl":"10.24875/AIDSRev.24000010","url":null,"abstract":"<p><p>HIV epidemics still exist as a major global public health burden, especially in middle- and low-income countries. Given the lack of approved vaccines, antiretroviral therapy (ART) remains the primary approach to reduce the mortality and morbidity linked to this disease. Effective treatment for HIV-1 requires the simultaneous administration of multiple drugs. However, the virus can show resistance to antiretroviral drugs, resulting in treatment failure. Therefore, this study focused on assessing the prevalence of mutations within the Indian HIV-positive population. After assessing the data, we intended to identify the most effective highly active ART (HAART) regimens for individuals with drug-resistant variants. Furthermore, our analysis revealed a spectrum of HIV mutations, with varying effects on protein stability. The significance of this analysis lies in its potential to optimize HAART selection for HIV-positive individuals by accounting for both prevalence and stability-altering mutations. By considering mutation effects on protein stability, we can modify treatment regimens, increasing the likelihood of therapy success and diminishing the risk of resistance. Moreover, this study contributes to the broader field of drug repurposing, offering insights into the rational design of antiretroviral therapies.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 3","pages":"93-101"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDS reviewsPub Date : 2024-01-01DOI: 10.24875/AIDSRev.24000002
Jan Vesterbacka, Anna-Karin Svensson, Piotr Nowak
{"title":"HTLV in Sweden.","authors":"Jan Vesterbacka, Anna-Karin Svensson, Piotr Nowak","doi":"10.24875/AIDSRev.24000002","DOIUrl":"10.24875/AIDSRev.24000002","url":null,"abstract":"<p><p>Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups such as HTLV-2 among intravenous drug users (IVDU) and people originating from HTLV-1 highly endemic areas. Thus, in the most recent study from 2012, the prevalence of HTLV-2 among IVDU in Stockholm was 3.2%. However, much of the epidemiological data on HTLV in Sweden stems from studies conducted primarily between the 1990s and 2007, and the impact of migration to Sweden during the past 15 years has not been evaluated. Despite Sweden's status as a country with generally low prevalence of HTLV, it is prudent to anticipate and prepare for several potential challenges associated with HTLV infection in the future. Proactive measures to enhance awareness, alongside strategies to curtail transmission and mitigate complications, are crucial for addressing this relatively rare, but significant health issue. In this work, we review the current epidemiological knowledge about HTLV in Sweden and discuss future Swedish perspectives.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 1","pages":"41-47"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140292518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDS reviewsPub Date : 2024-01-01DOI: 10.24875/AIDSRev.24000011
Jos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, Manuel Vélez-Díaz-Pallarés, Antonio Castro, Darío Rubio-Rodríguez, Carlos Rubio-Terrés
{"title":"HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review.","authors":"Jos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, Manuel Vélez-Díaz-Pallarés, Antonio Castro, Darío Rubio-Rodríguez, Carlos Rubio-Terrés","doi":"10.24875/AIDSRev.24000011","DOIUrl":"https://doi.org/10.24875/AIDSRev.24000011","url":null,"abstract":"<p><p>We describe and analyze resistance-associated mutations (RM) and virological failures (VF) on antiretroviral therapy using the latest approved integrase inhibitors (INIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB), together with their companion drugs in fixed-dose formulations: BIC/emtricitabine/tenofovir; CAB/rilpivirine; DTG/abacavir/lamivudine; DTG/emtricitabine/tenofovir; and DTG/lamivudine. Systematic literature searches were conducted in PubMed and other electronic databases for clinical studies published between January 2010 and May 2023, according to preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA), which analyzed VFs and RMs of INIs. Fifty clinical studies were included in the synthesis. VF in antiretroviral treatment (ART)-naïve patients occurred in 0.7-4.0%, 0.6-1.4%, and 0.6-9.0% of patients treated with DTG, BIC, and CAB, respectively. VF was reported in patients with previous ART in 0-8.1%, 0-2.0%, and 0.4-2.3% of those treated with DTG, BIC, and CAB, respectively. RMs were detected in ART-naïve patients in only one study with DTG (0.3%), none of the studies with BIC, and three of the studies with CAB (0.1-5.4%). In ART-experienced patients, RMs were detected in 0-1.9% of DTG-treated patients. No cases of RM were detected in the 11 BIC studies reviewed. In the case of CAB, RMs were detected in eight studies, ranging from 0.3% to 1.9% of patients. In conclusion, RM rates in the studies reviewed were generally low using the latest INIs. This review identified BIC as the INI with the lowest number of observed VF and lack of RM.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 2","pages":"67-79"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDS reviewsPub Date : 2023-12-15DOI: 10.24875/AIDSRev.M23000066
Vicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, José V Fernández-Montero, Ana Treviño, Octavio Corral, Fernando de Jesús, Pablo Barreiro
{"title":"Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals.","authors":"Vicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, José V Fernández-Montero, Ana Treviño, Octavio Corral, Fernando de Jesús, Pablo Barreiro","doi":"10.24875/AIDSRev.M23000066","DOIUrl":"10.24875/AIDSRev.M23000066","url":null,"abstract":"<p><p>Viruses cause a large burden of human infectious diseases. During the past 50 years, antivirals have been developed to treat many pathogenic viruses, including herpesviruses, retroviruses, hepatitis viruses, and influenza. Besides being used as treatment, antivirals have shown efficacy for preventing certain viral infections. Following the success in the HIV field, a renewed interest has emerged on the use of antivirals as prophylaxis for other viruses. The development of formulations with extended half-life has pushed further this consideration in persons at risk for a wide range of viral infections. In this way, long-acting antivirals might behave as \"chemovaccines\" when classical vaccines do not exist, cannot be recommended, immune responses are suboptimal, escape mutants emerge, and/or immunity wanes. Five main caveats would temper its use, namely, selection of drug resistance, drug interactions, short- and long-term side effects, potential teratogenicity in women of child-bearing age, and high cost. Herein, we discuss the prospects for long-acting antivirals as prophylaxis of human viral infections other than HIV.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":" ","pages":"162-172"},"PeriodicalIF":2.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138796864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}